3 results about "Autologous cell" patented technology

The application discloses a gp96 tumor neoantigen prediction method and application thereof, and relates to the technical field of tumor neoantigen prediction. The method comprises the following steps: S1, isolation and purification of gp96-tumor polypeptide complexes; S2, dissociation and purification of polypeptides; S3, mass spectrometric identification and sequence analysis of mutant peptides; S4, MHC affinity prediction; and S5, immunogenicity verification. The application takes gp96 as a natural biological concentrator, the captured polypeptides include products in a natural antigen processing path of tumor cells, and antigen peptide segments with potential immunological significance are enriched. In combination with MHC affinity prediction and immunogenicity function verification, the true positive rate of neoantigen screening is significantly improved. In a verification experiment on colon cancer samples, among 7 candidate neoantigens obtained through prediction, 4 can significantly activate autologous T cells of a patient to secrete IFN-gamma, and show a high immunogenicity verification positive rate.

This disclosure relates to a tumor immunotherapy composition, preparation method, and application based on specific immune cells, particularly specific immune cells activated by attenuated Listeria monocytogenes carrying non-integrating antigenic peptide plasmids. The disclosure involves extracting T cells in vitro, co-culturing T cells with antigen-presenting cells activated by attenuated Listeria monocytogenes, and generating T cells with specific tumor antigenic peptides in vitro. These specific T cells are then reinfused into the body to generate a tumor-specific immune response. The technical solution of this disclosure can specifically activate tumor-specific T cells, thereby triggering a series of anti-tumor immune responses. Furthermore, the process does not require genetic modification of autologous cells, significantly improving both targeting and safety.

Disclosed are methods of isolating T cells having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation, the method comprising: identifying one or more genes in a nucleic acid of a patient cancer cell, each gene containing a cancer-specific mutation encoding a mutated amino acid sequence; inducing autologous APCs of the patient to present the mutated amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs presenting the mutated amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of making a cell population, a plurality of cell populations, a pharmaceutical composition, and a method of treating or preventing cancer.